5 Solid Dividend Stocks to Buy Now

The article recommends a diversified five-stock dividend basket spanning Coca-Cola, PepsiCo, JPMorgan, Realty Income and AbbVie, with indicated yields ranging from 1.77% to 5.58%. JPMorgan recently raised its quarterly dividend 10% to $1.65, PepsiCo raised its payout 4% and Realty Income increased its monthly dividend to $0.2715, while each company is presented as having dividend coverage based on cash flow, earnings/capital, AFFO or adjusted earnings. The investment case is balanced by sector-specific risks including PepsiCo volume pressure, JPMorgan credit costs, Realty Income rate sensitivity and AbbVie patent erosion.

Analysis

The highest-conviction relative-value setup is PEP versus KO. PEP’s depressed multiple already discounts a prolonged North American snack-volume problem, while its yield provides meaningful carry; KO requires sustained mid-single-digit volume/price execution to defend a premium multiple despite a lower income return. A stabilization in Frito-Lay volumes over the next 1-3 quarters would drive both earnings-estimate durability and multiple expansion for PEP, whereas KO’s downside is primarily multiple compression if event-driven demand fails to convert into repeat consumption.

O is not simply a defensive yield substitute: its equity value is a leveraged claim on the spread between acquisition cap rates and marginal financing costs. The data-center/private-capital initiatives can improve long-term fee and asset-growth optionality, but they also increase execution and capital-markets dependence; a sustained rise in long-end Treasury yields would impair both its external-growth model and valuation simultaneously. The market may be underpricing tenant-cycle risk because sub-investment-grade exposure can weaken precisely when refinancing windows close, making occupancy a lagging rather than leading indicator.

JPM offers the strongest capital-return optionality but is increasingly a late-cycle operating-leverage trade, not a pure dividend compounder. Credit normalization, regulatory capital changes, and elevated expense growth could redirect excess capital from buybacks toward reserves within 1-3 quarters; that would matter more to the multiple than to the cash dividend. ABBV’s core thesis rests on franchise concentration: continued immunology growth must exceed the combined drag from mature-product erosion and acquisition-related dilution, so investors should demand clean evidence in prescription trends and post-deal guidance rather than rely on adjusted-earnings coverage alone.

Contrarianly, this basket is more correlated than its sector labels imply: slower nominal consumption pressures both staples; restrictive rates affect O directly and consumer credit indirectly through JPM; and a recession would compress all five valuation frameworks despite nominal dividend continuity. There is no broad basket trade at current information quality; the useful opportunity is dispersion, with PEP valuation recovery and selective O rate hedging offering clearer asymmetry.

Key Decisions for Investors

• Initiate a 3-6 month long PEP / short KO pair, sized beta-neutral. Target a 10-15% relative gain from PEP multiple normalization and KO premium compression; exit if PEP reports another quarter of broad North American volume deterioration or cuts its earnings framework.
• Maintain/accumulate JPM only on credit-spread or market-volatility pullbacks over the next 1-3 months, rather than chase capital-return headlines. Use a 8-10% downside stop or reassess if reserve builds accelerate materially, card losses worsen, or buyback capacity is reduced.
• Treat O as a rate-sensitive income allocation rather than a standalone growth position: pair a long O position with a partial short in IYR or use Treasury-duration hedges. Add only if long-end yields stabilize and incremental investment spreads remain demonstrably above marginal funding costs; a sustained 50 bp rise in the 10-year yield is thesis-negative.
• Hold ABBV only with a defined 6-12 month catalyst checklist: immunology growth, mature-product erosion, and updated post-acquisition EPS guidance. Reduce if the combined growth of Skyrizi/Rinvoq decelerates sharply or management expands deal-related dilution beyond initial guidance; verify all pipeline and acquisition claims independently before adding.
• Avoid adding KO at its current quality premium unless upcoming results demonstrate that volume-led growth, rather than pricing and temporary marketing activity, is carrying the earnings outlook. A missed volume/price-mix print would be the preferred entry signal for a later long.